BENEFICIAL EFFECTS OF FENOLDOPAM TREATMENT ON RENAL FUNCTION IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

REFERENCES

• Lackovic Z., Relja M. Evidence for a widely distributed peripheral dopaminergic system. Fed. Proc. 1983; 42(13)3000–3004
   PubMedGoogle Scholar
• Holden R. J. Schizophrenia, suicide and the serotonin story. Med. Hypotheses 1995; 44/5: 379–391
   Web of Science ®Google Scholar
• Levin B. E. Glucose‐regulated dopamine release from substantia nigra neurons. Brain Res. 2000; 874(2)158–164
   PubMed Web of Science ®Google Scholar
• Saller C. F. Dopaminergic activity is reduced in diabetic rats. Neurosci. Lett. 1984; 49(3)301–306
   PubMed Web of Science ®Google Scholar
• Figlewicz D. P., Brot M. D., McCall A. L., Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat, a molecular study. Brain Res. 1996; 736: (1–2)–54–60
   Google Scholar
• Lim D. K., Lee K. M., Ho I. K. Changes in the central dopaminergic systems in the streptozotocin-induced diabetic rats. Arch. Pharm. Res. 1994; 17(6)398–404
   PubMedGoogle Scholar
• Liang Y., Lubkin M., Sheng H., Scislowski P. W., Cincotta H. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and elevated basal insulin release from islets of ob/ob mice. Biochim. Biophys. Acta 1998; 1405: (1–3)–1–13
   Web of Science ®Google Scholar
• Cincotta A. H., Tozzo E., Scislowski P. W. Bromocriptine/SKF 38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci. 1997; 61(10)951–956
   PubMed Web of Science ®Google Scholar
• Cincotta A. H., Meier A. H., Cincotta Jr M. Bromocriptine improves glycemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin. Investig. Drugs 1999; 8(10)1683–1707
   PubMedGoogle Scholar
• Scislowski P. W., Tozzo E., Zhang Y., Phaneuf S., Prevelige R., Cincotta A. H. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int. J. Obes. Relat. Metab. Disord. 1999; 23(4)425–431
   PubMed Web of Science ®Google Scholar
• Liang Y., Jetton T. L., Lubkin M., Meier A. H., Cincotta A. H. Bromocriptine/SKF 38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell. Mol. Life. Sci. 1998; 54(7)703–711
   PubMed Web of Science ®Google Scholar
• O‘Hare J. P., Roland J. M., Walters G., Corall R.J. M. Impaired sodium retention in response to volume expansion induced by water immersion in insulin dependent diabetes mellitus. Diabetes Res. 1986; 3: 213–215
   PubMedGoogle Scholar
• DeChatel R., Wiedmann P., Flammer J., Zeigler W. H., Beretta‐Piccoli C., Vetter W., Reubi F. C. Sodium, renin, aldosterone, catecholamines and blood pressure in diabetes mellitus. Kidney Int. 1977; 12: 412–421
   PubMed Web of Science ®Google Scholar
• Feldt-Rasmussen B., Mathiesen E. R., Deckert T., Geise J., Christersen N. J., Bent-Hansen L., Nielsen M. D. Central role of sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone, and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Dibetologia 1987; 30: 610–617
   PubMed Web of Science ®Google Scholar
• Lee M. R. Dopamine and the kidney. Clin. Sci. 1982; 312: 77–83
   Google Scholar
• Hegde S. S., Jadhav A. L., Lokhandwala M. F. Role of kidney dopamine in the natriuretic response to volume expansion in rats. Hypertension 1989; 13: 828–834
   PubMed Web of Science ®Google Scholar
• Segers O., Dupont A. G., Gerlo E., Somers G. Decreased urinary dopamine excretion and disturbed dopamine/sodium relationship in type 1 diabetes mellitus. Diabet. Med. 1995; 12(3)229–234
   PubMed Web of Science ®Google Scholar
• Segers O., Dupont A. G., Gerlo E., Somers G. Urinary sodium and dopamine excretion: role of hyperinsulinaemia in dopamine production. Med. Sci. Res. 1996; 24: 72–73
   Google Scholar
• Hussain T., Beheray S. A., Lokhandwala M. F. Defective dopamine receptor function in proximal tubules of obese Zucker rats. Hypertension 1999; 34: 1091–1096
   PubMed Web of Science ®Google Scholar
• Chinoy N. J., Rao M. V., Derasari K. J., Highland H. N. Essential techniques in reproductive physiology and endocrinology.
   Google Scholar
• Hofteizer B., Carpenter A. M. Comparision of STZ induced diabetes in rats, including volumetric quantitation of pancreatic islet cells. Diabetologia 1973; 9: 178–184
   PubMed Web of Science ®Google Scholar
• Kocak G., Aktan F., Canbolat O., Ozogul C., Elbeg S., Yildizoglu–Ari N., Karasu C. Alpha‐lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin‐diabetes. Diabetes Nutr. Metab. 2000; 13(6)308–318
   PubMedGoogle Scholar
• Hakim Z. S., Goyal R. K. Comparative evaluation of different rat models with co‐existing diabetes mellitus and hypertension. Ind. J. Physiol. Pharmacol 2000; 44(2)125–135
   PubMedGoogle Scholar
• Fitzgerald S. M., Brands M. W. Nitric oxide may be required to prevent hypertension at the onset diabetes. Am. J. Physiol. Endocrinol. Metab. 2000; 279(4)E762–E768
   PubMed Web of Science ®Google Scholar
• Ozcelikay A. T., Tay A., Guner S., Tasyaran V., Yildizoglu‐Ari N., Dincer U. D., Altan V. M. Reversal effects of L‐arginine treatment on blood pressure and vascular responsiveness of streptozotocin‐diabetic rats. Pharmacol. Res. 2000; 41(2)201–209
   PubMed Web of Science ®Google Scholar
• Suanarunsawat T., Klongpanichapak S., Chaiyabutr N. Role of nitric oxide in renal function in rats with short and prolonged periods of streptozotocin‐induced diabetes. Diabetes Obes Metab 1999; 1(6)339–346
   PubMed Web of Science ®Google Scholar
• Barthelmebs M., Mayer P., Thomas A., Grima M., Imbs J. L. Pathophysiological role of dopamine in kidney: effect in diabetes mellitus and after contralateral nephrectomy. Hypertens. Res. 1995; 18(1)S131–S136
   PubMedGoogle Scholar
• Mann W. A., Sosnowski G. F., Kavanagh B. J., Erickson R. W., Brennan F. J., Wjebelhaus V. D. Comparative properties of two benzazepine renal vasodilator compounds. Fed. Proc. 1981; 40: 647
   Google Scholar
• Ackerman D. M., Weinstock J., Weibelhaus V. D., Berkowitz B. Renal vasodilators and hypertension. Drug Dev. Res. 1982; 2: 283–297
   Web of Science ®Google Scholar
• Felder C. C., Campbell T., Albrecht F., Jose P. A. Dopamine inhibits Na+−H+-exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am. J. Physiol., 259: F297–F303
   Google Scholar
• Chen C. J., Lokhandwala M. F. Inhibition of Na+,K+-ATPase in rat renal proximal tubules by dopamine involved D1‐like dopamine receptor activation. Naunyn Schmiedebergs Arch. Pharmacol. 1993; 347: 289–295
   PubMed Web of Science ®Google Scholar
• Rasch R. Prevention of diabetic glomerullopathy in streptozotocin diabetic rats by insulin treatment: kidney size and glomerular volume. Dibetologia 1979; 16: 125–128
   PubMed Web of Science ®Google Scholar
• Rasch R. Prevention of diabetic glomerullopathy in streptozotocin diabetic rats by insulin treatment. Dibetologia 1980; 18: 413–416
   PubMed Web of Science ®Google Scholar
• Hansen S. K. Renal hypertrophy in experimental diabetes. Kidney Int. 1983; 23: 643–646
   PubMed Web of Science ®Google Scholar
• Cortes P., Lewin N. W., Dumler F., Rubenstein H., Verghese C. P., Venkatachalam K. K. Uridine triphosphate and RNA synthesis during diabetes induced kidney growth. Am. J. Physiol. 1980; 238: E349–E357
   PubMed Web of Science ®Google Scholar